cd154 Search Results


pme cd40l dc stimulation  (Miltenyi Biotec)
94
Miltenyi Biotec pme cd40l dc stimulation
Pme Cd40l Dc Stimulation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pme cd40l dc stimulation/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
pme cd40l dc stimulation - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
cd40l  (Sino Biological)
93
Sino Biological cd40l
Cd40l, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd40l/product/Sino Biological
Average 93 stars, based on 1 article reviews
cd40l - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
cd154 microbead kit  (Miltenyi Biotec)
93
Miltenyi Biotec cd154 microbead kit
Cd154 Microbead Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd154 microbead kit/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
cd154 microbead kit - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti cd154 mab  (Bio X Cell)
95
Bio X Cell anti cd154 mab
Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg <t>anti-CD154</t> mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.
Anti Cd154 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd154 mab/product/Bio X Cell
Average 95 stars, based on 1 article reviews
anti cd154 mab - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
trap thrombinreceptor agonist peptide 6  (MedChemExpress)
94
MedChemExpress trap thrombinreceptor agonist peptide 6
Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg <t>anti-CD154</t> mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.
Trap Thrombinreceptor Agonist Peptide 6, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trap thrombinreceptor agonist peptide 6/product/MedChemExpress
Average 94 stars, based on 1 article reviews
trap thrombinreceptor agonist peptide 6 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
anti human cd154  (Cytek Biosciences)
93
Cytek Biosciences anti human cd154
Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg <t>anti-CD154</t> mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.
Anti Human Cd154, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd154/product/Cytek Biosciences
Average 93 stars, based on 1 article reviews
anti human cd154 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti cd154 apc  (Miltenyi Biotec)
93
Miltenyi Biotec anti cd154 apc
Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg <t>anti-CD154</t> mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.
Anti Cd154 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd154 apc/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti cd154 apc - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
fitc anti human cd154  (Miltenyi Biotec)
93
Miltenyi Biotec fitc anti human cd154
Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg <t>anti-CD154</t> mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.
Fitc Anti Human Cd154, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc anti human cd154/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
fitc anti human cd154 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
cd154 macs enrichment  (Miltenyi Biotec)
93
Miltenyi Biotec cd154 macs enrichment
Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg <t>anti-CD154</t> mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.
Cd154 Macs Enrichment, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd154 macs enrichment/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
cd154 macs enrichment - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti cd154 pe  (Miltenyi Biotec)
93
Miltenyi Biotec anti cd154 pe
Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg <t>anti-CD154</t> mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.
Anti Cd154 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd154 pe/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti cd154 pe - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
cd40lg  (Proteintech)
93
Proteintech cd40lg
<t>CD40LG</t> is down-regulated in multiple cancer types, and this down-regulation has significant prognostic implications. (A) Violin plots showed the differential expression of CD40LG in 34 cancer types compared with normal tissues. (B) Body map showing CD40LG expression levels in various normal human tissues. (C) Cox regression analysis of OS demonstrated the prognostic role of CD40LG in a variety of cancers. (D) Cox regression analysis of PFS demonstrated the prognostic role of CD40LG in a variety of cancers. (E) The veen diagram shows those cancers in which CD40LG has the same prognostic predictive efficacy in OS and PFS.
Cd40lg, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd40lg/product/Proteintech
Average 93 stars, based on 1 article reviews
cd40lg - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
anti human cd154 vioblue  (Miltenyi Biotec)
93
Miltenyi Biotec anti human cd154 vioblue
<t>CD40LG</t> is down-regulated in multiple cancer types, and this down-regulation has significant prognostic implications. (A) Violin plots showed the differential expression of CD40LG in 34 cancer types compared with normal tissues. (B) Body map showing CD40LG expression levels in various normal human tissues. (C) Cox regression analysis of OS demonstrated the prognostic role of CD40LG in a variety of cancers. (D) Cox regression analysis of PFS demonstrated the prognostic role of CD40LG in a variety of cancers. (E) The veen diagram shows those cancers in which CD40LG has the same prognostic predictive efficacy in OS and PFS.
Anti Human Cd154 Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd154 vioblue/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti human cd154 vioblue - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg anti-CD154 mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.

Journal: JCI Insight

Article Title: Allograft dendritic cell p40 homodimers activate donor-reactive memory CD8 + T cells

doi: 10.1172/jci.insight.96940

Figure Lengend Snippet: Groups of C57BL/6 (n = 4/group) mice received A/J cardiac allografts subjected to 8 hours of CIS. On days 0 and 1 after transplant, all recipients were injected with 100 μg BrdU i.p. and either 250 μg control rat IgG or (A) 250 μg CTLA-4Ig or (B) 250 μg anti-CD154 mAb. After 48 hours, allografts were harvested and digested, and aliquots of single cell suspensions were stained with antibody and analyzed by flow cytometry, with examples of gating as shown for each allograft sample to assess and quantitate the BrdU incorporation of infiltrating memory CD4+ and CD8+ T cells.***P < 0.001, as determined by the Mann-Whitney nonparametric test. (C) Groups of C57BL/6 recipient mice (n = 5–6/group) received A/J cardiac allografts subjected to 8 hours of CIS and, on days 0 and 1 after transplant, were treated with 250 μg control rat IgG, 250 μg CTLA-4Ig, or 250 μg anti-CD154 mAb i.p. Allograft survival was monitored by daily abdominal palpation, and rejection was confirmed by laparotomy. **P < 0.01 versus 8 hours of CIS + IgG or + CTLA-4Ig, as determined using the Log-rank/Mantel-Cox test.

Article Snippet: Anti-CD154 mAb (MR-1, Bio X Cell) was administered at 0.25 mg i.p. daily on days 0 and +1.

Techniques: Injection, Staining, Flow Cytometry, BrdU Incorporation Assay, MANN-WHITNEY

CD40LG is down-regulated in multiple cancer types, and this down-regulation has significant prognostic implications. (A) Violin plots showed the differential expression of CD40LG in 34 cancer types compared with normal tissues. (B) Body map showing CD40LG expression levels in various normal human tissues. (C) Cox regression analysis of OS demonstrated the prognostic role of CD40LG in a variety of cancers. (D) Cox regression analysis of PFS demonstrated the prognostic role of CD40LG in a variety of cancers. (E) The veen diagram shows those cancers in which CD40LG has the same prognostic predictive efficacy in OS and PFS.

Journal: Journal of Cancer

Article Title: CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes

doi: 10.7150/jca.115525

Figure Lengend Snippet: CD40LG is down-regulated in multiple cancer types, and this down-regulation has significant prognostic implications. (A) Violin plots showed the differential expression of CD40LG in 34 cancer types compared with normal tissues. (B) Body map showing CD40LG expression levels in various normal human tissues. (C) Cox regression analysis of OS demonstrated the prognostic role of CD40LG in a variety of cancers. (D) Cox regression analysis of PFS demonstrated the prognostic role of CD40LG in a variety of cancers. (E) The veen diagram shows those cancers in which CD40LG has the same prognostic predictive efficacy in OS and PFS.

Article Snippet: Subsequently, they were incubated with the primary antibody against GAPDH (1:1,000, 60004-1-lg, Proteintech) and CD40LG (1:1,000, 16668-1-AP, Proteintech) at 4°C overnight.

Techniques: Quantitative Proteomics, Expressing

Correlation Between CD40LG Expression and Immunotherapeutic Efficacy of Various Cancers. (A) Kaplan-Meier plotter analysis showing that patients with high CD40LG expression have better OS after immunotherapy. (B) Kaplan-Meier plotter analysis showing that patients with high CD40LG expression have better PFS after immunotherapy. (C) Comparison of CD40LG expression with traditional biomarkers including PD-L1 expression, TMB, MSI status and CD8+T cell density in predicting immunotherapy outcomes across 25 datasets.

Journal: Journal of Cancer

Article Title: CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes

doi: 10.7150/jca.115525

Figure Lengend Snippet: Correlation Between CD40LG Expression and Immunotherapeutic Efficacy of Various Cancers. (A) Kaplan-Meier plotter analysis showing that patients with high CD40LG expression have better OS after immunotherapy. (B) Kaplan-Meier plotter analysis showing that patients with high CD40LG expression have better PFS after immunotherapy. (C) Comparison of CD40LG expression with traditional biomarkers including PD-L1 expression, TMB, MSI status and CD8+T cell density in predicting immunotherapy outcomes across 25 datasets.

Article Snippet: Subsequently, they were incubated with the primary antibody against GAPDH (1:1,000, 60004-1-lg, Proteintech) and CD40LG (1:1,000, 16668-1-AP, Proteintech) at 4°C overnight.

Techniques: Expressing, Comparison

The important role of CD40LG expression in LUAD. (A-C) Reduced expression of CD40LG in LUAD was analysed in public databases, including TCGA, GSE118370 and GSE43458 . (D-F) The association of CD40LG expression with overall survival of LUAD patients was examined in public databases, including GSE30219 , GSE31210 and GSE72094 . (G) CD40LG expression in LUADs analysed in immunohistochemistry of HPA was lower than in corresponding paraneoplastic tissues. (H) PCR experiments were performed on four patients with LUAD to verify the RNA expression of CD40LG in cancer and corresponding paracancerous tissues. (I) Western blot experiments were performed on four patients with LUAD to verify the protein expression of CD40LG in cancer and corresponding paracancerous tissues.

Journal: Journal of Cancer

Article Title: CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes

doi: 10.7150/jca.115525

Figure Lengend Snippet: The important role of CD40LG expression in LUAD. (A-C) Reduced expression of CD40LG in LUAD was analysed in public databases, including TCGA, GSE118370 and GSE43458 . (D-F) The association of CD40LG expression with overall survival of LUAD patients was examined in public databases, including GSE30219 , GSE31210 and GSE72094 . (G) CD40LG expression in LUADs analysed in immunohistochemistry of HPA was lower than in corresponding paraneoplastic tissues. (H) PCR experiments were performed on four patients with LUAD to verify the RNA expression of CD40LG in cancer and corresponding paracancerous tissues. (I) Western blot experiments were performed on four patients with LUAD to verify the protein expression of CD40LG in cancer and corresponding paracancerous tissues.

Article Snippet: Subsequently, they were incubated with the primary antibody against GAPDH (1:1,000, 60004-1-lg, Proteintech) and CD40LG (1:1,000, 16668-1-AP, Proteintech) at 4°C overnight.

Techniques: Expressing, Immunohistochemistry, RNA Expression, Western Blot

CD40LG Expression Correlates with Immune Microenvironment in LUAD. (A) Correlation between CD40LG expression and Immunophenoscore (IPS), including components such as antigen presentation, effector cells, suppressor cells, and immune checkpoints in LUAD. (B-F) Positive correlation of CD40LG expression with infiltration of various immune cells in LUAD tissues, including CD8+ T cells, dendritic cells, macrophages, B cells, and CD4+ T cells, using multiple predictive methods.

Journal: Journal of Cancer

Article Title: CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes

doi: 10.7150/jca.115525

Figure Lengend Snippet: CD40LG Expression Correlates with Immune Microenvironment in LUAD. (A) Correlation between CD40LG expression and Immunophenoscore (IPS), including components such as antigen presentation, effector cells, suppressor cells, and immune checkpoints in LUAD. (B-F) Positive correlation of CD40LG expression with infiltration of various immune cells in LUAD tissues, including CD8+ T cells, dendritic cells, macrophages, B cells, and CD4+ T cells, using multiple predictive methods.

Article Snippet: Subsequently, they were incubated with the primary antibody against GAPDH (1:1,000, 60004-1-lg, Proteintech) and CD40LG (1:1,000, 16668-1-AP, Proteintech) at 4°C overnight.

Techniques: Expressing, Immunopeptidomics

CD40LG Expression in LUAD and its Association with Clinical Stages. (A) Representative immunohistochemical staining images of CD40LG in primary LUAD tissues and corresponding paracancerous tissues. (B) Boxplot comparing CD40LG expression levels in tumor tissues versus paracancerous tissues. (C-D) The boxplot analysis illustrates the expression of CD40LG in relation to TNM and T stages.

Journal: Journal of Cancer

Article Title: CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes

doi: 10.7150/jca.115525

Figure Lengend Snippet: CD40LG Expression in LUAD and its Association with Clinical Stages. (A) Representative immunohistochemical staining images of CD40LG in primary LUAD tissues and corresponding paracancerous tissues. (B) Boxplot comparing CD40LG expression levels in tumor tissues versus paracancerous tissues. (C-D) The boxplot analysis illustrates the expression of CD40LG in relation to TNM and T stages.

Article Snippet: Subsequently, they were incubated with the primary antibody against GAPDH (1:1,000, 60004-1-lg, Proteintech) and CD40LG (1:1,000, 16668-1-AP, Proteintech) at 4°C overnight.

Techniques: Expressing, Immunohistochemical staining, Staining

CD40LG Expression Correlated with Immune Infiltrate Patterns in LUAD. (A) Representative mIF staining image showing CD40LG expression and immune cell distribution in LUAD tissue microarrays. (B-E) Correlation analysis between CD40LG_IHC_Score and percentages of various immune-related cells in total, tumor, and stromal regions.

Journal: Journal of Cancer

Article Title: CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes

doi: 10.7150/jca.115525

Figure Lengend Snippet: CD40LG Expression Correlated with Immune Infiltrate Patterns in LUAD. (A) Representative mIF staining image showing CD40LG expression and immune cell distribution in LUAD tissue microarrays. (B-E) Correlation analysis between CD40LG_IHC_Score and percentages of various immune-related cells in total, tumor, and stromal regions.

Article Snippet: Subsequently, they were incubated with the primary antibody against GAPDH (1:1,000, 60004-1-lg, Proteintech) and CD40LG (1:1,000, 16668-1-AP, Proteintech) at 4°C overnight.

Techniques: Expressing, Staining

CD40LG Expression and Its Effects on LUAD Cell Migration, Invasion, and Proliferation. (A) Western blot analysis of CD40LG expression in five LUAD cell lines. (B) Western blot verification of siRNA-mediated knockdown of CD40LG in H1975 cells and overexpression in A549 cells. (C) EDU assay results showing increased proliferation upon CD40LG knockdown in H1975 cells and decreased proliferation with CD40LG overexpression in A549 cells. (D) Scratch wound healing assay indicating enhanced migration with CD40LG knockdown in H1975 cells and reduced migration with CD40LG overexpression in A549 cells. (E) Transwell assay demonstrating increased migration and invasion capabilities with CD40LG knockdown in H1975 cells and decreased capabilities with CD40LG overexpression in A549 cells.

Journal: Journal of Cancer

Article Title: CD40LG Downregulation in Lung Adenocarcinoma: A Prognostic Biomarker Linked to Immune Cell Infiltration and Survival Outcomes

doi: 10.7150/jca.115525

Figure Lengend Snippet: CD40LG Expression and Its Effects on LUAD Cell Migration, Invasion, and Proliferation. (A) Western blot analysis of CD40LG expression in five LUAD cell lines. (B) Western blot verification of siRNA-mediated knockdown of CD40LG in H1975 cells and overexpression in A549 cells. (C) EDU assay results showing increased proliferation upon CD40LG knockdown in H1975 cells and decreased proliferation with CD40LG overexpression in A549 cells. (D) Scratch wound healing assay indicating enhanced migration with CD40LG knockdown in H1975 cells and reduced migration with CD40LG overexpression in A549 cells. (E) Transwell assay demonstrating increased migration and invasion capabilities with CD40LG knockdown in H1975 cells and decreased capabilities with CD40LG overexpression in A549 cells.

Article Snippet: Subsequently, they were incubated with the primary antibody against GAPDH (1:1,000, 60004-1-lg, Proteintech) and CD40LG (1:1,000, 16668-1-AP, Proteintech) at 4°C overnight.

Techniques: Expressing, Migration, Western Blot, Knockdown, Over Expression, EdU Assay, Wound Healing Assay, Transwell Assay